Phi Therapeutics is a microbiome company structured around changing the way chronic bacterial diseases are treated. As an alternative therapies for antibiotics - that kill good and bad bacteria indiscriminately and cause dysbiosis and worsen the problem of drug-resistance - from start-up, the firm has been working on groundbreaking technology designed to revolutionize the standard approach. Initially focused on acne, eczema and other cronic bacterial skin diseases -- especially for those having sensitive skin - the firm's effort is anchored in three years of intensive research by the principals on the skin microbiome. Pi Therapeutics has developed a microbiome editing platform that allows the performance of both additive and subtractive functions on the microbiome. Using this approach, itibecomes possible simply to "weed out" the pathogen without disturbing the good microbiota, and to replace it with a probiotic species.
